Risk factors for the degradation of lung elastic fibers in the ventilated neonate. Implications for impaired lung development in bronchopulmonary dysplasia.
In order to evaluate the risk for proteolytic destruction of lung parenchymal elastic fibers in ventilated premature infants, the concentrations of elastase were determined in tracheal aspirates of 65 infants from whom we obtained a total of 327 sequential samples. Elastase was detected at least once in 39 of the 65 infants studied. Eleven of these infants were ventilated with greater than 60% oxygen for greater than 5 days. In 19 infants, the presence of elastase was associated with positive bacterial and/or viral cultures and/or elevated ratios (greater than 0.22) of immature neutrophils to total neutrophils. Elastase was not detected in the lung secretions of 26 infants ventilated with greater than 60% oxygen for less than 3 days, suggesting minimal risk for elastic fiber destruction in the intubated infant who neither has pneumonia nor requires prolonged hyperoxic ventilation. The risk for elastic fiber destruction was further evaluated by analyzing sequential urine and tracheal aspirate samples for the presence of an elastolytic degradation product of elastin (desmosine). The biochemical data indicated a potential risk for proteolytic destruction of elastic fibers in association with infection and/or prolonged hyperoxic exposure. In addition, autopsy specimens obtained from three of the infants revealed structurally abnormal lung parenchymal elastic fibers. Because elastic fibers are believed to provide the structural support for alveolar septal development, proteolytic degradation of these fibers may be a significant factor in the impaired lung development that occurs in infants with bronchopulmonary dysplasia.
Bruce
M C
MC
Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio.
Schuyler
M
M
Martin
R J
RJ
Starcher
B C
BC
Tomashefski
J F
JF
Wedig
K E
KE
D001997:Bronchopulmonary Dysplasia / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D003895:Desmosine / Q000652:urine; D004547:Elastic Tissue / Q000473:pathology*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D008168:Lung / Q000473:pathology*; D008297:Male; D010196:Pancreatic Elastase / Q000378:metabolism; D012121:Respiration, Artificial / Q000009:adverse effects*; D012307:Risk Factors; D014132:Trachea / Q000737:chemistry / Q000201:enzymology
D003895:Desmosine; D010196:Pancreatic Elastase